Page last updated: 2024-10-19

thioctic acid and Asthma, Bronchial

thioctic acid has been researched along with Asthma, Bronchial in 7 studies

Thioctic Acid: An octanoic acid bridged with two sulfurs so that it is sometimes also called a pentanoic acid in some naming schemes. It is biosynthesized by cleavage of LINOLEIC ACID and is a coenzyme of oxoglutarate dehydrogenase (KETOGLUTARATE DEHYDROGENASE COMPLEX). It is used in DIETARY SUPPLEMENTS.

Research Excerpts

ExcerptRelevanceReference
"Obesity is already responsible for 300,000 deaths per year."1.51The influence of apocynin, lipoic acid and probiotics on antioxidant enzyme levels in the pulmonary tissues of obese asthmatic mice. ( Kleniewska, P; Pawliczak, R, 2019)
" In conclusion, mGST in combination with GSH has a synergistic effect in reducing airway inflammation compared to the individual antioxidants and has potential for the treatment of asthma."1.36Mutated glutathione S-transferase in combination with reduced glutathione shows a synergistic effect in ameliorating oxidative stress and airway inflammation. ( Arora, N; Nair, S; Singh, BP; Tripathi, P, 2010)

Research

Studies (7)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (42.86)29.6817
2010's3 (42.86)24.3611
2020's1 (14.29)2.80

Authors

AuthorsStudies
Kleniewska, P2
Pawliczak, R2
Tripathi, P1
Nair, S1
Singh, BP1
Arora, N1
Park, SJ3
Lee, KS3
Lee, SJ1
Kim, SR3
Park, SY1
Jeon, MS1
Lee, HB1
Lee, YC3
Cho, YS1
Lee, J1
Lee, TH1
Lee, EY1
Lee, KU1
Park, JY1
Moon, HB1
Park, HS1
Min, KH2
Jin, SM2
Park, KH1
Kim, UH1
Kim, CY1
Lee, KY1
Yoo, WH1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Exploratory Study of Lipoic Acid Supplementation on Oxidative Stress, Inflammatory and Functional Markers in Asthmatic Patients: Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Clinical Trial.[NCT01221350]55 participants (Actual)Interventional2010-11-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Induced Sputum Carbonylated Proteins at Baseline

Proteins can become modified by a large number of reactions involving reactive oxygen species. Among these, carbonylation is an irreversible and unrepairable oxidative reaction. The main protein modifications originated from oxidative stress comprise direct oxidation of aminoacids with a thiol group, such as cysteine, oxidative glycation, and carbonylation. Oxidative protein carbonylation induce protein degradation in a nonspecific manner. Chemically, oxidative carbonylation preferentially occurs at proline, threonine, lysine, and arginine, presumably through a metal-catalyzed activation of hydrogen peroxide to a reactive intermediate. Carbonylation usually refers to a process that forms reactive ketones or aldehydes that can be reacted by 2,4-dinitrophenylhydrazine (DNPH) to form hydrazones. Direct oxidation of side chains of lysine, arginine, proline, and threonine residues, among other aminoacids, produces DNPH detectable protein products (NCT01221350)
Timeframe: Baseline

Interventionnmol/mg (Mean)
Lipoic Acid7.5
Placebo10.12

Induced Sputum Carbonylated Proteins at Endpoint

Proteins can become modified by a large number of reactions involving reactive oxygen species. Among these, carbonylation is an irreversible and unrepairable oxidative reaction. The main protein modifications originated from oxidative stress comprise direct oxidation of aminoacids with a thiol group, such as cysteine, oxidative glycation, and carbonylation. Oxidative protein carbonylation induce protein degradation in a nonspecific manner. Chemically, oxidative carbonylation preferentially occurs at proline, threonine, lysine, and arginine, presumably through a metal-catalyzed activation of hydrogen peroxide to a reactive intermediate. Carbonylation usually refers to a process that forms reactive ketones or aldehydes that can be reacted by 2,4-dinitrophenylhydrazine (DNPH) to form hydrazones. Direct oxidation of side chains of lysine, arginine, proline, and threonine residues, among other aminoacids, produces DNPH detectable protein products. (NCT01221350)
Timeframe: 60 days

Interventionnmol/mg (Mean)
Lipoic Acid3.24
Placebo4.21

Induced Sputum Eosinophils at Baseline

Eosinophils, a prominent feature of asthma, are found in increased numbers in the circulation and sputum, usually in relation to the severity of asthma. (NCT01221350)
Timeframe: Baseline

InterventionEosinophil percentage in sputum cells (Mean)
Lipoic Acid12.88
Placebo6.10

Induced Sputum Eosinophils at Endpoint

Eosinophils, a prominent feature of asthma, are found in increased numbers in the circulation and sputum, usually in relation to the severity of asthma. (NCT01221350)
Timeframe: 60 days

InterventionEosinophil percentage in sputum cells (Mean)
Lipoic Acid6.39
Placebo5.68

Induced Sputum of Glutathione (GSH)/Glutathione Disulfide (GSSG) Ratio at Baseline

Induced sputum of GSH and GSSG levels at baseline. The ratio GSH/GSSG is considered an index of antioxidant status and reductive -SH groups. GSH and GSSG were measured by a microplate fluorescent assay. (NCT01221350)
Timeframe: Baseline

Interventionratio (Mean)
Lipoic Acid81.42
Placebo35.77

Induced Sputum of Glutathione (GSH)/Glutathione Disulfide (GSSG) Ratio at Endpoint

Change in the induced sputum of antioxidant parameters GSH and GSSG levels after 60 days of treatment. The ratio GSH/GSSG is considered an index of antioxidant status and reductive -SH groups. GSH and GSSG were measured by a microplate fluorescent assay. (NCT01221350)
Timeframe: 60 days

Interventionratio (Mean)
Lipoic Acid58.6
Placebo37.5

Inflammatory IL-4 Sputum Levels at Endpoint

Inflammatory IL-4 sputum levels after 60 days of treatment. Sputum induction is a semi-invasive technique used to detect and monitor airway inflammation. IL-4 is a Th2 cytokine that promote airway inflammation in asthma. IL-4 drives the production of IgE in B cells. IL-4 was measured by ELISA. (NCT01221350)
Timeframe: 60 days

Interventionpg/mL (Mean)
Lipoic Acid14.53
Placebo23.19

Inflammatory Interleukin-4 (IL-4) Sputum Levels at Baseline

Inflammatory IL-4 sputum levels after 60 days of treatment. Sputum induction is a semi-invasive technique used to detect and monitor airway inflammation. IL-4 is a Th2 cytokine that promote airway inflammation in asthma. IL-4 drives the production of immunoglobulin E (IgE) in B cells. IL-4 was measured by ELISA. (NCT01221350)
Timeframe: Baseline

Interventionpg/mL (Mean)
Lipoic Acid37.77
Placebo39.90

Measurement of Quality of Life With the ACT (Asthma Control Test) at Baseline

Assessment of Quality of life scores with the ACT (Asthma Control Test). The ACT is a way to determine if the asthma symptoms are well controlled. The Asthma Control Test™ (ACT™) is a five question health survey used to measure asthma control in individuals 12 years of age and older. The survey measures the elements of asthma control as defined by the National Heart, Lung, and Blood Institute (NHLBI). ACT is an efficient, reliable, and valid method of measuring asthma control, with or without, lung functioning measures such as spirometry. Each item includes 5 response options corresponding to a 5-point Likert-type rating scale. In scoring the ACT survey, responses for each of the 5 items are summed to yield a score ranging from 5 (poor control of asthma) to 25 (complete control of asthma). (NCT01221350)
Timeframe: Baseline

Interventionunits on a scale (Mean)
Lipoic Acid13.65
Placebo14.46

Measurement of Quality of Life With the ACT (Asthma Control Test) at Endpoint

Assessment of Quality of life scores with the ACT (Asthma Control Test). The ACT is a way to determine if the asthma symptoms are well controlled. The Asthma Control Test™ (ACT™) is a five question health survey used to measure asthma control in individuals 12 years of age and older. The survey measures the elements of asthma control as defined by the National Heart, Lung, and Blood Institute (NHLBI). ACT is an efficient, reliable, and valid method of measuring asthma control, with or without, lung functioning measures such as spirometry. Each item includes 5 response options corresponding to a 5-point Likert-type rating scale. In scoring the ACT survey, responses for each of the 5 items are summed to yield a score ranging from 5 (poor control of asthma) to 25 (complete control of asthma). (NCT01221350)
Timeframe: 60 days

Interventionunits on a scale (Mean)
Lipoic Acid19.13
Placebo17.71

Measurement of Quality of Life With the AQLQ (Asthma Quality of Life Questionnaire) at Baseline

"The Asthma Quality of Life Questionnaire (AQLQ) was developed to measure the functional problems (physical, emotional, social and occupational) that are most troublesome to adults (17-70 years) with asthma.~There are 32 questions in the AQLQ and they are in 4 domains (symptoms, activity limitation, emotional function and environmental stimuli). The activity domain contains 5 'patient-specific' questions. This allows patients to select 5 activities in which they are most limited and these activities will be assessed at each follow-up. Patients are asked to think about how they have been during the previous two weeks and to respond to each of the 32 questions on a 7-point scale (7 = not impaired at all - 1 = severely impaired). The overall AQLQ score is the mean of all 32 responses and the individual domain scores are the means of the items in those domains (http://www.qoltech.co.uk/aqlq.html)." (NCT01221350)
Timeframe: Baseline

Interventionunits on a scale (Mean)
Lipoic Acid3.86
Placebo3.72

Measurement of Quality of Life With the AQLQ (Asthma Quality of Life Questionnaire) at Endpoint

"The Asthma Quality of Life Questionnaire (AQLQ) was developed to measure the functional problems (physical, emotional, social and occupational) that are most troublesome to adults (17-70 years) with asthma.~There are 32 questions in the AQLQ and they are in 4 domains (symptoms, activity limitation, emotional function and environmental stimuli). The activity domain contains 5 'patient-specific' questions. This allows patients to select 5 activities in which they are most limited and these activities will be assessed at each follow-up. Patients are asked to think about how they have been during the previous two weeks and to respond to each of the 32 questions on a 7-point scale (7 = not impaired at all - 1 = severely impaired). The overall AQLQ score is the mean of all 32 responses and the individual domain scores are the means of the items in those domains (http://www.qoltech.co.uk/aqlq.html)." (NCT01221350)
Timeframe: 60 days

Interventionunits on a scale (Mean)
Lipoic Acid5.57
Placebo5.10

Spirometric FEF Values at Baseline

Measurement of spirometric parameters at baseline: Forced expiratory flow (FEF) is the flow (or speed) of air coming out of the lung during the middle portion of a forced expiration. (NCT01221350)
Timeframe: Baseline

InterventionLiters/sec (Mean)
Lipoic Acid4.89
Placebo6.09

Spirometric FEF Values at Endpoint

Measurement of spirometric FEF after 60 days of treatment: Forced expiratory flow (FEF) is the flow (or speed) of air coming out of the lung during the middle portion of a forced expiration. (NCT01221350)
Timeframe: 60 days

InterventionLiters/sec (Mean)
Lipoic Acid5.47
Placebo6.10

Spirometric FEV1 Values at Baseline

Measurement of spirometric predicted parameters at baseline: Forced expiratory volume in 1 second (FEV1), volume that has been exhaled at the end of the first second of forced expiration. (NCT01221350)
Timeframe: Baseline

InterventionLiters (Mean)
Lipoic Acid2.01
Placebo2.37

Spirometric FEV1 Values at Endpoint

Measurement of spirometric predicted parameters after 60 days of treatment. Forced expiratory volume in 1 second (FEV1), volume that has been exhaled at the end of the first second of forced expiration. (NCT01221350)
Timeframe: 60 days

InterventionLiters (Mean)
Lipoic Acid2.26
Placebo2.35

Spirometric FVC Values at Baseline

Measurement of spirometric predicted parameters at baseline. Forced vital capacity (FVC) is the volume of air that can forcibly be blown out after full inspiration, measured in liters. (NCT01221350)
Timeframe: Baseline

InterventionLiters (Mean)
Lipoic Acid2.74
Placebo3.07

Spirometric FVC Values at Endpoint

Measurement of spirometric predicted parameters at the baseline and after 60 days of treatment: Forced vital capacity (FVC) is the volume of air that can forcibly be blown out after full inspiration, measured in liters. (NCT01221350)
Timeframe: 60 days

InterventionLiters (Mean)
Lipoic Acid2.82
Placebo3.06

Other Studies

7 other studies available for thioctic acid and Asthma, Bronchial

ArticleYear
Does Oxidative Stress Along with Dysbiosis Participate in the Pathogenesis of Asthma in the Obese?
    Cell biochemistry and biophysics, 2023, Volume: 81, Issue:1

    Topics: Animals; Asthma; Diet, High-Fat; Dysbiosis; Hydrogen Peroxide; Mice; Mice, Inbred C57BL; Obesity; Ox

2023
The influence of apocynin, lipoic acid and probiotics on antioxidant enzyme levels in the pulmonary tissues of obese asthmatic mice.
    Life sciences, 2019, Oct-01, Volume: 234

    Topics: Acetophenones; Animals; Antioxidants; Asthma; Catalase; Glutathione Peroxidase; Lung; Male; Mice, In

2019
Mutated glutathione S-transferase in combination with reduced glutathione shows a synergistic effect in ameliorating oxidative stress and airway inflammation.
    Free radical biology & medicine, 2010, Mar-15, Volume: 48, Issue:6

    Topics: Animals; Antioxidants; Asthma; Disease Models, Animal; Drug Synergism; Glutathione; Glutathione Tran

2010
L-2-Oxothiazolidine-4-carboxylic acid or α-lipoic acid attenuates airway remodeling: involvement of nuclear factor-κB (NF-κB), nuclear factor erythroid 2p45-related factor-2 (Nrf2), and hypoxia-inducible factor (HIF).
    International journal of molecular sciences, 2012, Volume: 13, Issue:7

    Topics: Airway Remodeling; Animals; Anti-Asthmatic Agents; Anti-Inflammatory Agents; Asthma; Basic Helix-Loo

2012
alpha-Lipoic acid inhibits airway inflammation and hyperresponsiveness in a mouse model of asthma.
    The Journal of allergy and clinical immunology, 2004, Volume: 114, Issue:2

    Topics: Animals; Asthma; Bronchial Hyperreactivity; DNA; Immunoglobulin E; Inflammation; Lung; Male; Methach

2004
A prodrug of cysteine, L-2-oxothiazolidine-4-carboxylic acid, regulates vascular permeability by reducing vascular endothelial growth factor expression in asthma.
    Molecular pharmacology, 2005, Volume: 68, Issue:5

    Topics: Animals; Asthma; Capillary Permeability; Female; Mice; Mice, Inbred BALB C; Ovalbumin; Phosphatidyli

2005
Antioxidant down-regulates interleukin-18 expression in asthma.
    Molecular pharmacology, 2006, Volume: 70, Issue:4

    Topics: Animals; Antioxidants; Asthma; Bronchial Hyperreactivity; Bronchoalveolar Lavage Fluid; Down-Regulat

2006